Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE versus EMTRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE versus EMTRIVA.
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE vs EMTRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emtricitabine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competing with natural substrates and causing chain termination after incorporation into viral DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to a hydrophobic pocket near the active site of HIV-1 reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
One tablet (200 mg emtricitabine/25 mg rilpivirine/300 mg tenofovir disoproxil fumarate) orally once daily with a meal.
Emtricitabine 200 mg orally once daily.
None Documented
None Documented
Emtricitabine: terminal half-life ~10 hours (clinical context: supports once-daily dosing; prolonged in renal impairment). Rilpivirine: terminal half-life ~50 hours (clinical context: supports once-daily dosing; long half-life allows missed dose forgiveness). Tenofovir: terminal half-life ~17 hours (clinical context: supports once-daily dosing; prolonged in renal impairment).
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Emtricitabine: 86% excreted unchanged in urine via glomerular filtration and active tubular secretion; 14% as metabolites. Rilpivirine: ~85% fecal as unchanged drug (25%) and metabolites (60%); ~6% urinary. Tenofovir disoproxil fumarate: 70-80% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Category A/B
Category C
NRTI
Antiretroviral, NRTI